| Hazard Information | Back Directory | [Uses]
BI 703704 is a potent soluble guanylate cyclase (sGC) activator. BI 703704 inhibits the progression of diabetic nephropathy in the ZSF1 rat[1]. | [in vivo]
BI 703704 (0.3-10 mg/kg; food intake; daily for 15 weeks) results in dose-dependent decreases in urinary protein excretion (UPE), and a dose-dependent increase in renal cGMP content[1].
BI 703704 is effective in elevating renal cGMP levels in a dose-dependent manner and in slowing the progression of diabetic nephropathy in an oxidative stress milieu[1]. | Animal Model: | Fifty-eight male ZSF1 rats (12-13 weeks)[1] | | Dosage: | 0.3, 1, 3, or 10 mg/kg | | Administration: | Food intake; daily for 15 weeks | | Result: | Resulted in dose-dependent decreases in urinary protein excretion (UPE), and a dose-dependent increase in renal cGMP content.
|
| [References]
[1] Boustany-Kari CM, et al. A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat. J Pharmacol Exp Ther. 2016 Mar;356(3):712-9. DOI:10.1124/jpet.115.230706 |
|
|